RNA Virus Infections Clinical Trial
Official title:
SARS -CoV-2 Detection in Saliva Samples: A Test Validation Protocol
This study aims to validate the use of human saliva as a substrate for an assay to detect SARS-CoV-2 and define accuracy, analytical sensitivity and specificity of the TaqPath RT-PCR test.
Investigators will carry out validation of a laboratory assay to detect SARS-CoV-2 nucleic acids in human saliva samples. Data for the validation will include the test results from standard nasopharyngeal (NP) swabs (controls) AND matched saliva samples (experimental group) of individuals who are either known to be infected or at high risk of being infected. Investigators hypothesize that the performance of an assay designed specifically for saliva will not perform differently, as defined by a predetermined margin, from the standard assay performed on NP and other respiratory samples ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
| Completed |
NCT04644484 -
A Phase III Clinical Study to Evaluate SYN023's Efficacy and Safety
|
Phase 3 | |
| Completed |
NCT00984945 -
Safety Study of a Plant-based H5 Virus-Like Particles (VLP) Vaccine in Healthy Adults
|
Phase 1 | |
| Active, not recruiting |
NCT05284097 -
Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study
|
Phase 2 | |
| Completed |
NCT03739112 -
Efficacy of a Plant-derived Quadrivalent Virus-like Particle (VLP) Vaccine in the Elderly
|
Phase 3 | |
| Completed |
NCT01991587 -
Safety, Tolerability and Immunogenicity of a Plant-made Seasonal Quadrivalent VLP Influenza Vaccine in Adults
|
Phase 1/Phase 2 | |
| Completed |
NCT03294473 -
Centralized Reminder Recall - Flu RCT2
|
N/A | |
| Completed |
NCT01244867 -
Immunogenicity, Safety, Tolerability of a Plant-Made H5 VLP Influenza Vaccine
|
Phase 2 | |
| Not yet recruiting |
NCT05394623 -
Prevalence and Burden of Hepatitis D Virus Infection in China Through Preoperative Examination Test (Predict Study)
|
||
| Recruiting |
NCT03776760 -
Strategies for Hepatitis C Testing and Treatment in Aboriginal Communities That Lead to Elimination
|
||
| Active, not recruiting |
NCT04365101 -
Natural Killer Cell (CYNK-001) Infusions in Adults With COVID-19
|
Phase 1/Phase 2 | |
| Completed |
NCT05307991 -
Integrating Enhanced HIV PrEP Into a STI Clinic in Lilongwe
|
||
| Completed |
NCT03110770 -
VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents
|
Phase 2 | |
| Completed |
NCT04772469 -
Self-Test Strategies and Linkage Incentives to Improve ART and PrEP Uptake in Men
|
N/A | |
| Terminated |
NCT02120274 -
Vitamin D and Vitamin B12 Supplementation With Pegylated Interferon-Alfa Plus Ribavirin for Treating Chronic Hepatitis C
|
Phase 4 | |
| Completed |
NCT02768805 -
Immunogenicity of a Quadrivalent Virus-Like Particles (VLP) Influenza Vaccine in Healthy Adults
|
Phase 2 | |
| Completed |
NCT03642977 -
DNA and RNA Viruses of the Blood Virome of Allogeneic Hematopoietic Stem Cell Transplant Recipients
|
||
| Recruiting |
NCT04627623 -
Prevalence and Risk Factors of COVID-19 in the Upper Silesian Agglomeration
|
||
| Completed |
NCT01991561 -
Immunogenicity, Safety, Tolerability of a Plant-made H5 Virus-like-particle (VLP) Influenza Vaccine.
|
Phase 2 | |
| Completed |
NCT01587131 -
DNA-based Influenza Vaccine in the Elderly
|
Phase 1 |